EUROFINS MEDIGENOMIX GMBH

Their core work

Eurofins Medigenomix is the genomics and genetic diagnostics division of the Eurofins Scientific group, one of Europe's largest laboratory testing networks, operating from Ebersberg near Munich, Germany. Their core business is professional DNA analysis, genomic sequencing, and genetic testing services delivered through a certified commercial laboratory infrastructure. In H2020 consortia, they function as specialist service providers — supplying high-quality genomic analysis capacity to research projects that need reliable, scalable testing rather than building that capability in-house. Their presence in both a neurodevelopmental disorders training network (MiND) and a quantitative biology programme (QUANTEXBIO) suggests their genomic services are applicable across a range of biological research contexts.

What they specialise in

How they've shifted over time

Both H2020 projects started in 2015, so there is no meaningful temporal shift within the CORDIS data to analyse. The early MiND project carried no recorded keywords, while QUANTEXBIO is associated with computational biology, plant sciences, biophysics, mathematics, and theoretical modelling — pointing toward quantitative life sciences rather than clinical diagnostics. If anything, this suggests the organisation's research partnerships diversified from a clinical-genomics starting point toward broader experimental and computational biology contexts. However, with only two projects and no post-2020 H2020 activity, any trend inference must be treated as speculative.

Their H2020 trajectory hints at a broadening from clinical genetic testing into support for quantitative and interdisciplinary biology research, though the data is too thin to call this a firm strategic direction.

How they like to work

Eurofins Medigenomix has never coordinated an H2020 project — they consistently join as participant or third party, signalling a service-provider role rather than a research-agenda driver. Their presence in MSCA training networks (ITN-ETN and COFUND) suggests they are valued for what they can deliver operationally — genomic testing infrastructure — rather than for leading scientific programmes. Working with them means engaging a commercial laboratory on defined service terms, not co-developing research strategy.

Despite only two projects, Eurofins Medigenomix connected with 41 unique partners across 16 countries, a figure that reflects the large consortium structures typical of MSCA training networks rather than their own networking activity. Their reach is European but the depth of bilateral relationships is impossible to assess from this data alone.

What sets them apart

As a commercial subsidiary of the Eurofins Scientific group — a publicly listed company with laboratories across Europe — Eurofins Medigenomix offers something most academic consortium partners cannot: certified, high-throughput genomic testing infrastructure with consistent quality standards. For a research consortium needing genetic analysis at scale, engaging them avoids the cost and time of building internal capacity. Their value proposition is reliability and accreditation, not scientific novelty.

Highlights from their portfolio

• MiND
  The only project for which they received EC funding (EUR 62,304), placing their genomic services directly in a clinical neuroscience training context focused on ADHD and autism spectrum disorders.
• QUANTEXBIO
  Their third-party role in this broad quantitative biology COFUND programme — covering plant sciences, biophysics, and theoretical modelling — demonstrates that their laboratory services extend well beyond clinical genetics.